References
- Aboutalebi H, Bahrami A, Soleimani A, Saeedi N, Rahmani F, Khazaei M, Fiuji H, Shafiee M, Ferns GA, Avan A, et al. The diagnostic, prognostic and therapeutic potential of circulating microRNAs in ovarian cancer. Int J Biochem Cell Biol. 2020;124:105765. doi:https://doi.org/10.1016/j.biocel.2020.105765
- Choe SR, Kim YN, Park CG, Cho KH, Cho DY, Lee HY. RCP induces FAK phosphorylation and ovarian cancer cell invasion with inhibition by curcumin. Exp Mol Med. 2018;50(4):1–10. doi:https://doi.org/10.1038/s12276-018-0078-1
- Dwivedi P, Yuan S, Han S, Mangrio FA, Zhu Z, Lei F, Ming Z, Cheng L, Liu Z, Si T, et al. Core-shell microencapsulation of curcumin in PLGA microparticles: programmed for application in ovarian cancer therapy. Artif Cells Nanomed Biotechnol. 2018;46(sup3):S481–S91. doi:https://doi.org/10.1080/21691401.2018.1499664
- Arzuman L, Beale P, Chan C, Yu JQ, Huq F. Synergism from combinations of tris (benzimidazole) monochloroplatinum (II) chloride with capsaicin, quercetin, curcumin and cisplatin in human ovarian cancer cell lines. Anticancer Res. 2014;34(10):5453–64.
- Cai Y-Y, Lin W-P, Li A-P, Xu J-Y. Combined effects of curcumin and triptolide on an ovarian cancer cell line. Asian Pac J Cancer Prev. 2013;14(7):4267–71. doi:https://doi.org/10.7314/apjcp.2013.14.7.4267
- Rath KS, McCann GA, Cohn DE, Rivera BK, Kuppusamy P, Selvendiran K. Safe and targeted anticancer therapy for ovarian cancer using a novel class of curcumin analogs. J Ovarian Res. 2013;6(1):35. doi:https://doi.org/10.1186/1757-2215-6-35
- Rahmani A, Alsahli MA, Aly SM, Khan MA, Aldebasi YH. Role of curcumin in disease prevention and treatment. Adv Biomed Res. 2018;7(1):38. doi:https://doi.org/10.4103/abr.abr_147_16
- Wang H, Zhang K, Liu J, Yang J, Tian Y, Yang C, Li Y, Shao M, Su W, Song N. Curcumin regulates cancer progression: Focus on ncRNAs and molecular signaling pathways. Front Oncol. 2021;11:660712. doi:https://doi.org/10.3389/fonc.2021.660712
- Sanphui P, Goud NR, Khandavilli UBR, Bhanoth S, Nangia A. New polymorphs of curcumin. Chem Commun (Camb). 2011;47(17):5013–5. doi:https://doi.org/10.1039/c1cc10204d
- Aggarwal BB, Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci. 2009;30(2):85–94. doi:https://doi.org/10.1016/j.tips.2008.11.002
- Maheshwari RK, Singh AK, Gaddipati J, Srimal RC. Multiple biological activities of curcumin: a short review. Life Sci. 2006;78(18):2081–7. doi:https://doi.org/10.1016/j.lfs.2005.12.007
- Parsamanesh N, Moossavi M, Bahrami A, Butler AE, Sahebkar A. Therapeutic potential of curcumin in diabetic complications. Pharmacol Res. 2018;136:181–93. doi:https://doi.org/10.1016/j.phrs.2018.09.012
- Bahrami A, Sathyapalan T, Moallem SA, Sahebkar A. Counteracting arsenic toxicity: Curcumin to the rescue? J Hazard Mater. 2020;400:123160. doi:https://doi.org/10.1016/j.jhazmat.2020.123160
- Shanmugam MK, Rane G, Kanchi MM, Arfuso F, Chinnathambi A, Zayed ME, Alharbi SA, Tan BKH, Kumar AP, Sethi G. The multifaceted role of curcumin in cancer prevention and treatment. Molecules. 2015;20(2):2728–69. doi:https://doi.org/10.3390/molecules20022728
- Bahrami A, A. Ferns G. Effect of curcumin and its derivates on gastric cancer: molecular mechanisms. Nutr Cancer. 2021;73(9):1553–69. doi:https://doi.org/10.1080/01635581.2020.1808232
- Bahrami A, Atkin SL, Majeed M, Sahebkar A. Effects of curcumin on hypoxia-inducible factor as a new therapeutic target. Pharmacol Res. 2018;137:159–69. doi:https://doi.org/10.1016/j.phrs.2018.10.009
- Marjaneh RM, Rahmani F, Hassanian SM, Rezaei N, Hashemzehi M, Bahrami A, Ariakia F, Fiuji H, Sahebkar A, Avan A, et al. Phytosomal curcumin inhibits tumor growth in colitis-associated colorectal cancer. J Cell Physiol. 2018;233(10):6785–98. doi:https://doi.org/10.1002/jcp.26538
- Jahanbakhshi F, Maleki Dana P, Badehnoosh B, Yousefi B, Mansournia MA, Jahanshahi M, Asemi Z, Halajzadeh J. Curcumin anti-tumor effects on endometrial cancer with focus on its molecular targets. Cancer Cell Int. 2021;21(1):120. doi:https://doi.org/10.1186/s12935-021-01832-z
- Banik U, Parasuraman S, Adhikary AK, Othman NH. Curcumin: the spicy modulator of breast carcinogenesis. J Exp Clin Cancer Res. 2017;36(1):1–16. doi:https://doi.org/10.1186/s13046-017-0566-5
- Jordan BC, Mock CD, Thilagavathi R, Selvam C. Molecular mechanisms of curcumin and its semisynthetic analogues in prostate cancer prevention and treatment. Life Sci. 2016;152:135–44. doi:https://doi.org/10.1016/j.lfs.2016.03.036
- Lelli D, Pedone C, Majeed M, Sahebkar A. Curcumin and lung cancer: the role of microRNAs. Curr Pharm Des. 2017;23(23):3440–4. doi:https://doi.org/10.2174/1381612823666170109144818
- Lelli D, Pedone C, Sahebkar A. Curcumin and treatment of melanoma: The potential role of microRNAs. Biomed Pharmacother. 2017;88:832–4. doi:https://doi.org/10.1016/j.biopha.2017.01.078
- Simental-Mendía LE, Caraglia M, Majeed M, Sahebkar A. Impact of curcumin on the regulation of microRNAs in colorectal cancer. Expert Rev Gastroenterol Hepatol. 2017;11(2):99–101. doi:https://doi.org/10.1080/17474124.2017.1268528
- Pan W, Yang H, Cao C, Song X, Wallin B, Kivlin R, Lu S, Hu G, Di W, Wan Y. AMPK mediates curcumin-induced cell death in CaOV3 ovarian cancer cells. Oncol Rep. 2008;20(6):1553–9.
- Shi M, Cai Q, Yao L, Mao Y, Ming Y, Ouyang G. Antiproliferation and apoptosis induced by curcumin in human ovarian cancer cells. Cell Biol Int. 2006;30(3):221–6. doi:https://doi.org/10.1016/j.cellbi.2005.10.024
- Ji C, Cao C, Lu S, Kivlin R, Amaral A, Kouttab N, Yang H, Chu W, Bi Z, Di W, et al. Curcumin attenuates EGF-induced AQP3 up-regulation and cell migration in human ovarian cancer cells. Cancer Chemother Pharmacol. 2008;62(5):857–65. doi:https://doi.org/10.1007/s00280-007-0674-6
- Yu Z, Wan Y, Liu Y, Yang J, Li L, Zhang W. Curcumin induced apoptosis via PI3K/Akt-signalling pathways in SKOV3 cells. Pharm Biol. 2016;54(10):2026–32. doi:https://doi.org/10.3109/13880209.2016.1139601
- Seo J-A, Kim B, Dhanasekaran DN, Tsang BK, Song YS. Curcumin induces apoptosis by inhibiting sarco/endoplasmic reticulum Ca2+ ATPase activity in ovarian cancer cells. Cancer Lett. 2016;371(1):30–7. doi:https://doi.org/10.1016/j.canlet.2015.11.021
- Liu L-D, Pang Y-X, Zhao X-R, Li R, Jin C-J, Xue J, Dong R-Y, Liu P-S. Curcumin induces apoptotic cell death and protective autophagy by inhibiting AKT/mTOR/p70S6K pathway in human ovarian cancer cells. Arch Gynecol Obstet. 2019;299(6):1627–39. doi:https://doi.org/10.1007/s00404-019-05058-3
- Weir NM, Selvendiran K, Kutala VK, Tong L, Vishwanath S, Rajaram M, Tridandapani S, Anant S, Kuppusamy P. Curcumin Induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK. Cancer Biol Ther. 2007;6(2):178–84. doi:https://doi.org/10.4161/cbt.6.2.3577
- Xiaoling M, Jing Z, Fang X, Liangdan T. Curcumin inhibits invasion and metastasis in the human ovarian cancer cells SKOV3 by CXCL12–CXCR4 axis. African Journal of Biotechnology. 2010;9:8230–4.
- Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, Armaiz-Pena GN, Kamat AA, Spannuth WA, Gershenson DM, Lutgendorf SK, et al. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor- B pathway. Clin Cancer Res. 2007;13(11):3423–30. doi:https://doi.org/10.1158/1078-0432.CCR-06-3072
- Zheng L-d, Tong Q-s, Wu C-h. Growth inhibition and apoptosis inducing mechanisms of curcumin on human ovarian cancer cell line A2780. Chin J Integr Med. 2006;12(2):126–31.
- Zhang J, Liu J, Xu X, Li L. Curcumin suppresses cisplatin resistance development partly via modulating extracellular vesicle-mediated transfer of MEG3 and miR-214 in ovarian cancer. Cancer Chemother Pharmacol. 2017;79(3):479–87. doi:https://doi.org/10.1007/s00280-017-3238-4
- Saydmohammed M, Joseph D, Syed V. Curcumin suppresses constitutive activation of STAT-3 by up-regulating protein inhibitor of activated STAT-3 (PIAS-3) in ovarian and endometrial cancer cells. J Cell Biochem. 2010;110(2):447–56. doi:https://doi.org/10.1002/jcb.22558
- Watson JL, Greenshields A, Hill R, Hilchie A, Lee PW, Giacomantonio CA, Hoskin DW. Curcumin-induced apoptosis in ovarian carcinoma cells is p53-independent and involves p38 mitogen-activated protein kinase activation and downregulation of Bcl-2 and survivin expression and Akt signaling. Mol Carcinog. 2010;49(1):13–24. doi:https://doi.org/10.1002/mc.20571
- Shin Y, Lee Y. Cytotoxic activity from Curcuma zedoaria through mitochondrial activation on ovarian cancer cells. Toxicol Res. 2013;29(4):257–61. doi:https://doi.org/10.5487/TR.2013.29.4.257
- Almosa H, Alqriqri M, Denetiu I, Baghdadi MA, Alkhaled M, Alhosin M, Aldajani WA, Zamzami M, Ucisik MH, Damiati S. Cytotoxicity of standardized curcuminoids mixture against epithelial ovarian cancer cell line SKOV-3. Sci Pharm. 2020;88(1):11. doi:https://doi.org/10.3390/scipharm88010011
- Du Z, Sha X. Demethoxycurcumin inhibited human epithelia ovarian cancer cells’ growth via up-regulating miR-551a. Tumour Biol. 2017;39(3):1010428317694302. doi:https://doi.org/10.1177/1010428317694302
- Zhao S-F, Zhang X, Zhang X-J, Shi X-Q, Yu Z-J, Kan Q-C. Induction of microRNA-9 mediates cytotoxicity of curcumin against SKOV3 ovarian cancer cells. Asian Pacific J Cancer Prev. 2014;15(8):3363–8. doi:https://doi.org/10.7314/APJCP.2014.15.8.3363
- Seo JH, Jeong KJ, Oh WJ, Sul HJ, Sohn JS, Kim YK, Cho DY, Kang JK, Park CG, Lee HY. Lysophosphatidic acid induces STAT3 phosphorylation and ovarian cancer cell motility: their inhibition by curcumin. Cancer Lett. 2010;288(1):50–6. doi:https://doi.org/10.1016/j.canlet.2009.06.023
- Yen H-Y, Tsao C-W, Lin Y-W, Kuo C-C, Tsao C-H, Liu C-Y. Regulation of carcinogenesis and modulation through Wnt/β-catenin signaling by curcumin in an ovarian cancer cell line. Sci Rep. 2019;9(1):1–14. doi:https://doi.org/10.1038/s41598-019-53509-3
- He M, Wang D, Zou D, Wang C, Lopes-Bastos B, Jiang WG, Chester J, Zhou Q, Cai J. Re-purposing of curcumin as an anti-metastatic agent for the treatment of epithelial ovarian cancer: in vitro model using cancer stem cell enriched ovarian cancer spheroids. Oncotarget. 2016;7(52):86374–87. doi:https://doi.org/10.18632/oncotarget.13413
- Kim MJ, Park K-S, Kim K-T, Gil EY. The inhibitory effect of curcumin via fascin suppression through JAK/STAT3 pathway on metastasis and recurrence of ovary cancer cells. BMC Women’s Health. 2020;20(1):1–9. doi:https://doi.org/10.1186/s12905-020-01122-2
- Mohebbati R, Anaeigoudari A, Khazdair MR. The effects of Curcuma longa and curcumin on reproductive systems. Endocr Regul. 2017;51(4):220–8. doi:https://doi.org/10.1515/enr-2017-0024
- Dan W, Cheng X, Fei-Fei Z, Bao-Jin Z. Effect of curcumin on the viability of SKOV3 cells and its probable mechanism of action. Trop J Pharm Res. 2022;20(4):767–70. doi:https://doi.org/10.4314/tjpr.v20i4.15
- Hu J, Verkman A, Hu J, Verkman A. Increased migration and metastatic potential of tumor cells expressing aquaporin water channels. FASEB J. 2006;20(11):1892–4. doi:https://doi.org/10.1096/fj.06-5930fje
- Xiang X, Saha AK, Wen R, Ruderman NB, Luo Z. AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Commun. 2004;321(1):161–7. doi:https://doi.org/10.1016/j.bbrc.2004.06.133
- Liduan Z, Qiangsong T, Cuihuan W. Growth-inhibitory effects of curcumin on ovary cancer cells and its mechanisms. J Huazhong Univ Sci Technol [Med Sci]. 2004;24(1):55–8. doi:https://doi.org/10.1007/BF02830706
- Yin Z, Sun J. Curcumin induces human SKOV3 cell apoptosis via the activation of Rho-kinase. Eur J Gynaecol Oncol. 2014;35:433–7.
- Herceg Z, Wang Z-Q. Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death. Mutat Res. 2001;477(1–2):97–110. doi:https://doi.org/10.1016/s0027-5107(01)00111-7
- Ayati A, Moghimi S, Salarinejad S, Safavi M, Pouramiri B, Foroumadi A. A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. Bioorg Chem. 2020;99:103811. doi:https://doi.org/10.1016/j.bioorg.2020.103811
- Burman C, Ktistakis NT. Regulation of autophagy by phosphatidylinositol 3-phosphate. FEBS Lett. 2010;584(7):1302–12. doi:https://doi.org/10.1016/j.febslet.2010.01.011
- Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, et al. Involvement of chemokine receptors in breast cancer metastasis. nature. 2001;410(6824):50–6. doi:https://doi.org/10.1038/35065016
- Moon C, Soria J-C, Jang SJ, Lee J, Obaidul Hoque M, Sibony M, Trink B, Chang YS, Sidransky D, Mao L. Involvement of aquaporins in colorectal carcinogenesis. Oncogene. 2003;22(43):6699–703. doi:https://doi.org/10.1038/sj.onc.1206762
- Chow PH, Bowen J, Yool AJ. Combined systematic review and transcriptomic analyses of mammalian aquaporin classes 1 to 10 as biomarkers and prognostic indicators in diverse cancers. Cancers. 2020;12(7):1911. doi:https://doi.org/10.3390/cancers12071911
- Meng Q, Xia C, Fang J, Rojanasakul Y, Jiang B-H. Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway. Cell Signal. 2006;18(12):2262–71. doi:https://doi.org/10.1016/j.cellsig.2006.05.019
- Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3’ kinase/AKT pathways. Oncogene. 2005;24(50):7443–54. doi:https://doi.org/10.1038/sj.onc.1209091
- Masuda M, Suzui M, Yasumatu R, et al. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res. 2002;62:3351–5.
- Hwang MH, Cho KH, Jeong KJ, Park Y-Y, Kim JM, Yu S-L, Park CG, Mills GB, Lee HY. RCP induces Slug expression and cancer cell invasion by stabilizing β1 integrin. Oncogene. 2017;36(8):1102–11. doi:https://doi.org/10.1038/onc.2016.277
- Liu X, Yan Z, Huang L, Guo M, Zhang Z, Guo C. Cell surface heat shock protein 90 modulates prostate cancer cell adhesion and invasion through the integrin-β1/focal adhesion kinase/c-Src signaling pathway. Oncol Rep. 2011;25(5):1343–51.
- Jeong BY, Cho KH, Yoon S-H, Park CG, Park H-W, Lee HY. Discoidin domain receptor 2 mediates lysophosphatidic acid-induced ovarian cancer aggressiveness. IJMS. 2021;22(10):5374. doi:https://doi.org/10.3390/ijms22105374
- Kryczek I, Wei S, Keller E, Liu R, Zou W. Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. Am J Physiol Cell Physiol. 2007;292(3):C987–C95. doi:https://doi.org/10.1152/ajpcell.00406.2006
- Fung AS, Kopciuk K, Dean ML, D’Silva A, Otsuka S, Klimowicz A, Hao D, Morris D, Bebb DG. CXCR4 expression in lung carcinogenesis: Evaluating gender-specific differences in survival outcomes based on CXCR4 expression in early stage non-small cell lung cancer patients. Plos One. 2021;16(1):e0241240. doi:https://doi.org/10.1371/journal.pone.0241240
- Xie L, Ushmorov A, Leithäuser F, Guan H, Steidl C, Färbinger J, Pelzer C, Vogel MJ, Maier HJ, Gascoyne RD, et al. FOXO1 is a tumor suppressor in classical Hodgkin lymphoma. Blood, the J Am Soc Hematol. 2012;119(15):3503–11. doi:https://doi.org/10.1182/blood-2011-09-381905
- Ide H, Mizushima T, Jiang G, Goto T, Nagata Y, Teramoto Y, Inoue S, Li Y, Kashiwagi E, Baras AS, et al. FOXO1 as a tumor suppressor inactivated via AR/ERβ signals in urothelial cells. Endocr Relat Cancer. 2020;27(4):231–44. doi:https://doi.org/10.1530/ERC-20-0004
- Pan S, Deng Y, Fu J, Zhang Y, Zhang Z, Ru X, Qin X. Decreased expression of ARHGAP15 promotes the development of colorectal cancer through PTEN/AKT/FOXO1 axis. Cell Death Dis. 2018;9(6):1–13. doi:https://doi.org/10.1038/s41419-018-0707-6
- Sastre-Perona A, Santisteban P. Role of the wnt pathway in thyroid cancer. Front Endocrinol (Lausanne). 2012;3:31. doi:https://doi.org/10.3389/fendo.2012.00031
- Nagendra PB, Goad J, Nielsen S, Rassam L, Lombard JM, Nahar P, Tanwar PS. Ovarian hormones through Wnt signalling regulate the growth of human and mouse ovarian cancer initiating lesions. Oncotarget. 2016;7(40):64836–53. doi:https://doi.org/10.18632/oncotarget.11711
- Nwani N, Condello S, Wang Y, Swetzig W, Barber E, Hurley T, Matei D. A novel ALDH1A1 inhibitor targets cells with stem cell characteristics in ovarian cancer. Cancers. 2019;11(4):502. doi:https://doi.org/10.3390/cancers11040502
- Arend RC, Londoño-Joshi AI, Samant RS, Li Y, Conner M, Hidalgo B, Alvarez RD, Landen CN, Straughn JM, Buchsbaum DJ. Inhibition of Wnt/β-catenin pathway by niclosamide: A therapeutic target for ovarian cancer. Gynecol Oncol. 2014;134(1):112–20. doi:https://doi.org/10.1016/j.ygyno.2014.04.005
- Panahi Y, Kianpour P, Mohtashami R, Jafari R, Simental-Mendía LE, Sahebkar A. Curcumin lowers serum lipids and uric acid in subjects with nonalcoholic fatty liver disease: a randomized controlled trial. J Cardiovasc Pharmacol. 2016;68(3):223–9. doi:https://doi.org/10.1097/FJC.0000000000000406
- Tan VY, Lewis SJ, Adams JC, Martin RM. Association of fascin-1 with mortality, disease progression and metastasis in carcinomas: a systematic review and meta-analysis. BMC Med. 2013;11(1):1–17. doi:https://doi.org/10.1186/1741-7015-11-52
- Li A, Morton JP, Ma Y, Karim SA, Zhou Y, Faller WJ, Woodham EF, Morris HT, Stevenson RP, Juin A, et al. Fascin is regulated by slug, promotes progression of pancreatic cancer in mice, and is associated with patient outcomes. Gastroenterol. 2014;146(5):1386–96.e17. doi:https://doi.org/10.1053/j.gastro.2014.01.046
- Chainoglou E, Hadjipavlou-Litina D. Curcumin analogues and derivatives with anti-proliferative and anti-inflammatory activity: Structural characteristics and molecular targets. Expert Opin Drug Discov. 2019;14(8):821–42. doi:https://doi.org/10.1080/17460441.2019.1614560
- Zhao S, Pi C, Ye Y, Zhao L, Wei Y. Recent advances of analogues of curcumin for treatment of cancer. Eur J Med Chem. 2019;180:524–35. doi:https://doi.org/10.1016/j.ejmech.2019.07.034
- Tang H, Murphy CJ, Zhang B, Shen Y, Van Kirk EA, Murdoch WJ, Radosz M. Curcumin polymers as anticancer conjugates. Biomaterials. 2010;31(27):7139–49. doi:https://doi.org/10.1016/j.biomaterials.2010.06.007
- Paulraj F, Abas F, H. Lajis N, Othman I, Naidu R. Molecular pathways modulated by curcumin analogue, diarylpentanoids in cancer. Biomolecules. 2019;9(7):270. doi:https://doi.org/10.3390/biom9070270
- Selvendiran K, Ahmed S, Dayton A, Kuppusamy ML, Tazi M, Bratasz A, Tong L, Rivera BK, Kálai T, Hideg K, et al. Safe and targeted anticancer efficacy of a novel class of antioxidant-conjugated difluorodiarylidenyl piperidones: differential cytotoxicity in healthy and cancer cells. Free Radic Biol Med. 2010;48(9):1228–35. doi:https://doi.org/10.1016/j.freeradbiomed.2010.02.009
- Selvendiran K, Tong L, Bratasz A, Kuppusamy ML, Ahmed S, Ravi Y, Trigg NJ, Rivera BK, Kálai T, Hideg K, et al. Anticancer efficacy of a difluorodiarylidenyl piperidone (HO-3867) in human ovarian cancer cells and tumor xenografts. Mol Cancer Ther. 2010;9(5):1169–79. doi:https://doi.org/10.1158/1535-7163.MCT-09-1207
- Tierney BJ, McCann GA, Cohn DE, Eisenhauer E, Sudhakar M, Kuppusamy P, Hideg K, Selvendiran K. HO-3867, a STAT3 inhibitor induces apoptosis by inactivation of STAT3 activity in BRCA1-mutated ovarian cancer cells. Cancer Biol Ther. 2012;13(9):766–75. doi:https://doi.org/10.4161/cbt.20559
- Selvendiran K, Ahmed S, Dayton A, Ravi Y, Kuppusamy ML, Bratasz A, Rivera BK, Kálai T, Hideg K, Kuppusamy P. HO-3867, a synthetic compound, inhibits the migration and invasion of ovarian carcinoma cells through downregulation of fatty acid synthase and focal adhesion kinase. Mol Cancer Res. 2010;8(9):1188–97. doi:https://doi.org/10.1158/1541-7786.MCR-10-0201
- Selvendiran K, Tong L, Vishwanath S, Bratasz A, Trigg NJ, Kutala VK, Hideg K, Kuppusamy P. EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression. J Biol Chem. 2007;282(39):28609–18. doi:https://doi.org/10.1074/jbc.M703796200
- Zhang X, Zhang H-Q, Zhu G-H, Wang Y-H, Yu X-C, Zhu X-B, Liang G, Xiao J, Li X-K. A novel mono-carbonyl analogue of curcumin induces apoptosis in ovarian carcinoma cells via endoplasmic reticulum stress and reactive oxygen species production. Mol Med Rep. 2012;5(3):739–44.
- Qu W, Xiao J, Zhang H, Chen Q, Wang Z, Shi H, Gong L, Chen J, Liu Y, Cao R, et al. B19, a novel monocarbonyl analogue of curcumin, induces human ovarian cancer cell apoptosis via activation of endoplasmic reticulum stress and the autophagy signaling pathway. Int J Biol Sci. 2013;9(8):766–77. doi:https://doi.org/10.7150/ijbs.5711
- Carew JS, Nawrocki ST, Cleveland JL. Modulating autophagy for therapeutic benefit. Autophagy. 2007;3(5):464–7. doi:https://doi.org/10.4161/auto.4311
- Lee W-H, Loo C-Y, Young PM, Traini D, Mason RS, Rohanizadeh R. Recent advances in curcumin nanoformulation for cancer therapy. Expert Opin Drug Deliv. 2014;11(8):1183–201. doi:https://doi.org/10.1517/17425247.2014.916686
- Hamam F. Curcumin: New weapon against cancer. FNS. 2014;05(22):2257–64. doi:https://doi.org/10.4236/fns.2014.522239
- Boztas AO, Karakuzu O, Galante G, Ugur Z, Kocabas F, Altuntas CZ, Yazaydin AO. Synergistic interaction of paclitaxel and curcumin with cyclodextrin polymer complexation in human cancer cells. Mol Pharm. 2013;10(7):2676–83. doi:https://doi.org/10.1021/mp400101k
- Seyed Hosseini E, Alizadeh Zarei M, Haddad Kashani H, Salimian M, Riahi Kashani N, Nikzad H. Altered long non-coding RNAs expression and cytotoxic and anti-proliferative activity of dendrosomal nano-curcumin in ovarian cancer cells. Indian J Gynecol Oncolog. 2021;19(2):37. doi:https://doi.org/10.1007/s40944-021-00511-1
- Sandhiutami NMD, Arozal W, Louisa M, Rahmat D, Wuyung PE. Curcumin nanoparticle enhances the anticancer effect of cisplatin by inhibiting PI3K/AKT and JAK/STAT3 pathway in rat ovarian carcinoma induced by DMBA. Front Pharmacol. 2020;11:603235. doi: https://doi.org/10.3389/fphar.2020.603235. Frontiers in Pharmacology| www frontiersin org11.
- Liu Z, Zhu Y-Y, Li Z-Y, Ning S-Q. Evaluation of the efficacy of paclitaxel with curcumin combination in ovarian cancer cells. Oncol Lett. 2016;12(5):3944–8. doi:https://doi.org/10.3892/ol.2016.5192
- Mancarella S, Greco V, Baldassarre F, Vergara D, Maffia M, Leporatti S. Polymer-coated magnetic nanoparticles for curcumin delivery to cancer cells. Macromol Biosci. 2015;15(10):1365–74. doi:https://doi.org/10.1002/mabi.201500142
- Riedel J, Calienni MN, Bernabeu E, Calabro V, Lázaro-Martinez JM, Prieto MJ, Gonzalez L, Martinez CS, Alonso S. d V, Montanari J, et al. Paclitaxel and curcumin co-loaded mixed micelles: Improving in vitro efficacy and reducing toxicity against Abraxane®. J Drug Delivery Sci Technol. 2021;62:102343. doi:https://doi.org/10.1016/j.jddst.2021.102343
- McCormick B, Lowes DA, Colvin L, Torsney C, Galley HF. MitoVitE, a mitochondria-targeted antioxidant, limits paclitaxel-induced oxidative stress and mitochondrial damage in vitro, and paclitaxel-induced mechanical hypersensitivity in a rat pain model. Br J Anaesth. 2016;117(5):659–66. doi:https://doi.org/10.1093/bja/aew309
- Gawde KA, Sau S, Tatiparti K, Kashaw SK, Mehrmohammadi M, Azmi AS, Iyer AK. Paclitaxel and di-fluorinated curcumin loaded in albumin nanoparticles for targeted synergistic combination therapy of ovarian and cervical cancers. Colloids Surf B Biointerfaces. 2018;167:8–19. doi:https://doi.org/10.1016/j.colsurfb.2018.03.046
- Luong D, Kesharwani P, Alsaab HO, Sau S, Padhye S, Sarkar FH, Iyer AK. Folic acid conjugated polymeric micelles loaded with a curcumin difluorinated analog for targeting cervical and ovarian cancers. Colloids Surf B Biointerfaces. 2017;157:490–502. doi:https://doi.org/10.1016/j.colsurfb.2017.06.025
- Abouzeid AH, Patel NR, Torchilin VP. Polyethylene glycol-phosphatidylethanolamine (PEG-PE)/vitamin E micelles for co-delivery of paclitaxel and curcumin to overcome multi-drug resistance in ovarian cancer. Int J Pharm. 2014;464(1–2):178–84. doi:https://doi.org/10.1016/j.ijpharm.2014.01.009
- Yallapu MM, Gupta BK, Jaggi M, Chauhan SC. Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. J Colloid Interface Sci. 2010;351(1):19–29. doi:https://doi.org/10.1016/j.jcis.2010.05.022
- Lev-Ari S, Strier L, Kazanov D, Madar-Shapiro L, Dvory-Sobol H, Pinchuk I, Marian B, Lichtenberg D, Arber N. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells. Clin Cancer Res. 2005;11(18):6738–44. doi:https://doi.org/10.1158/1078-0432.CCR-05-0171
- Koo JY, Kim HJ, Jung K-O, Park K-Y. Curcumin inhibits the growth of AGS human gastric carcinoma cells in vitro and shows synergism with 5-fluorouracil. J Med Food. 2004;7(2):117–21. doi:https://doi.org/10.1089/1096620041224229
- Liu Y, Chang RL, Cui XX, Newmark HL, Conney AH. Synergistic effects of curcumin on all-trans retinoic acid-and 1 alpha, 25-dihydroxyvitamin D3-induced differentiation in human promyelocytic leukemia HL-60 cells. Oncol Res. 1997;9(1):19–29.
- Hour T-C, Chen J, Huang C-Y, Guan J-Y, Lu S-H, Pu Y-S. Curcumin enhances cytotoxicity of chemotherapeutic agents in prostate cancer cells by inducing p21(WAF1/CIP1) and C/EBPbeta expressions and suppressing NF-kappaB activation. Prostate. 2002;51(3):211–8. doi:https://doi.org/10.1002/pros.10089
- Montopoli M, Ragazzi E, Froldi G, Caparrotta L. Cell-cycle inhibition and apoptosis induced by curcumin and cisplatin or oxaliplatin in human ovarian carcinoma cells. Cell Prolif. 2009;42(2):195–206. doi:https://doi.org/10.1111/j.1365-2184.2009.00585.x
- Zhao J, Pan Y, Li X, Zhang X, Xue Y, Wang T, Zhao S, Hou Y. Dihydroartemisinin and curcumin synergistically induce apoptosis in SKOV3 cells via upregulation of MiR-124 targeting midkine. Cell Physiol Biochem. 2017;43(2):589–601. doi:https://doi.org/10.1159/000480531
- Yang Y-l, Ji C, Cheng L, He L, Lu C-c, Wang R, Bi Z-g. Sphingosine kinase-1 inhibition sensitizes curcumin-induced growth inhibition and apoptosis in ovarian cancer cells. Cancer Sci. 2012;103(8):1538–45. doi:https://doi.org/10.1111/j.1349-7006.2012.02335.x
- Guo Q, Wu Y, Guo X, Cao L, Xu F, Zhao H, Zhu J, Wen H, Ju X, Wu X. The RNA-Binding Protein CELF2 inhibits ovarian cancer progression by stabilizing FAM198B. Mol Ther Nucleic Acids. 2021;23:169–84. doi:https://doi.org/10.1016/j.omtn.2020.10.011
- Melekoglu R, Ciftci O, Eraslan S, Cetin A, Basak N. Beneficial effects of curcumin and capsaicin on cyclophosphamide-induced premature ovarian failure in a rat model. J Ovarian Res. 2018;11(1):33. doi:https://doi.org/10.1186/s13048-018-0409-9
- Alhajamee M, Marai K, Al Abbas SMN, Homayouni Tabrizi M. Co-encapsulation of curcumin and tamoxifen in lipid-chitosan hybrid nanoparticles for cancer therapy. Mater Technol. 2021:1–12. doi:https://doi.org/10.1080/10667857.2021.1926811
- Zhao M-D, Li J-Q, Chen F-Y, Dong W, Wen L-J, Fei W-D, Zhang X, Yang P-L, Zhang X-M, Zheng C-H. Co-delivery of curcumin and paclitaxel by “core-shell” targeting amphiphilic copolymer to reverse resistance in the treatment of ovarian Cancer. Int J Nanomedicine. 2019;14:9453–67. doi:https://doi.org/10.2147/IJN.S224579
- Shah K, Mirza S, Desai U, et al. Synergism of curcumin and cytarabine in the down regulation of multi-drug resistance genes in acute myeloid leukemia. Anti-Cancer Agents in Med Chem (Formerly Current Medicinal Chemistry-Anti-Cancer Agents). 2016;16:128–35.
- Murakami M, Ohnuma S, Fukuda M, Chufan EE, Kudoh K, Kanehara K, Sugisawa N, Ishida M, Naitoh T, Shibata H, et al. Synthetic analogs of curcumin modulate the function of multidrug resistance-linked ATP-binding cassette transporter ABCG2. Drug Metab Dispos. 2017;45(11):1166–77. doi:https://doi.org/10.1124/dmd.117.076000
- Arzuman L, Beale P, Yu JQ, Huq F. Synthesis of tris (quinoline) monochloroplatinum (II) chloride and its activity alone and in combination with capsaicin and curcumin in human ovarian Cancer cell lines. Anticancer Res. 2016;36(6):2809–18.
- Baghbani F, Moztarzadeh F. Bypassing multidrug resistant ovarian cancer using ultrasound responsive doxorubicin/curcumin co-deliver alginate nanodroplets. Colloids Surf B Biointerfaces. 2017;153:132–40. doi:https://doi.org/10.1016/j.colsurfb.2017.01.051
- Karimpour M, Feizi MAH, Mahdavi M, Krammer B, Verwanger T, Najafi F, Babaei E. Development of curcumin-loaded gemini surfactant nanoparticles: Synthesis, characterization and evaluation of anticancer activity against human breast cancer cell lines. Phytomedicine. 2019;57:183–90. doi:https://doi.org/10.1016/j.phymed.2018.11.017
- Ebrahimi M, Babaei E, Neri F, Feizi MAH. Anti-proliferative and apoptotic effect of gemini curcumin in p53-wild type and p53-mutant colorectal cancer cell lines. Int J Pharm. 2021;601:120592. doi:https://doi.org/10.1016/j.ijpharm.2021.120592
- Ghaderi S, Babaei E, Hussen BM, Mahdavi M, Azeez HJ. Gemini curcumin suppresses proliferation of ovarian cancer OVCAR-3 cells via induction of apoptosis. ACAMC. 2021;21(6):775–81. doi:https://doi.org/10.2174/1871520620666200807223340
- Cornelison R, Llaneza DC, Landen CN. Emerging therapeutics to overcome chemoresistance in epithelial ovarian cancer: a mini-review. IJMS. 2017;18(13_Supplement):4924. doi:https://doi.org/10.1158/1538-7445.AM2018-4924
- Levy AS, Rathinavelu A, Coelho N, et al. Evaluation of the efficacy of curcumin and Y15 in platinum resistant ovarian cancer cells. AACR. 2018;78(13_Supplement):4924. doi:https://doi.org/10.1158/1538-7445.AM2018-4924
- Yallapu MM, Maher DM, Sundram V, Bell MC, Jaggi M, Chauhan SC. Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth. J Ovarian Res. 2010;3:11. doi:https://doi.org/10.1186/1757-2215-3-11
- Safaei R, Larson BJ, Cheng TC, Gibson MA, Otani S, Naerdemann W, Howell SB. Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol Cancer Ther. 2005;4(10):1595–604. doi:https://doi.org/10.1158/1535-7163.MCT-05-0102
- Pink RC, Samuel P, Massa D, Caley DP, Brooks SA, Carter DRF. The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells. Gynecol Oncol. 2015;137(1):143–51. doi:https://doi.org/10.1016/j.ygyno.2014.12.042
- Marsters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D, Yuan J, Gurney A, Goddard AD, Godowski P, et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol. 1997;7(12):1003–6. doi:https://doi.org/10.1016/S0960-9822(06)00422-2
- Tomek S, Horak P, Pribill I, Haller G, Rössler M, Zielinski CC, Pils D, Krainer M. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs. Gynecol Oncol. 2004;94(1):107–14. doi:https://doi.org/10.1016/j.ygyno.2004.04.012
- Lane D, Cartier A, L’Espérance S, Côté M, Rancourt C, Piché A. Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells. Gynecol Oncol. 2004;93(3):594–604. doi:https://doi.org/10.1016/j.ygyno.2004.03.029
- Wahl H, Tan L, Griffith K, Choi M, Liu JR. Curcumin enhances Apo2L/TRAIL-induced apoptosis in chemoresistant ovarian cancer cells. Gynecol Oncol. 2007;105(1):104–12. doi:https://doi.org/10.1016/j.ygyno.2006.10.050